

United States Patent and Trademark Office

cic

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	1	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/960,477	09/24/2001		Yuji Ishihara	2001-1276	6807
513	7590	05/31/2005		EXAMINER	
	•	ND & PONACK, L	TRUONG, TAMTHOM NGO		
2033 K STREET N. W. SUITE 800			ART UNIT	PAPER NUMBER	
WASHINGTON, DC 20006-1021				1624	
				DATE MAILED: 05/31/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action

Application No.	Applicant(s)	
09/960,477	ISHIHARA ET AL.	
Examiner	Art Unit	
Tamthom N. Truong	1624	

Potoro the Eiling of an Annual Priof			
Before the Filing of an Appeal Brief	Examiner	Art Unit	
	Tamthom N. Truong	1624	
The MAILING DATE of this communication appe	ars on the cover sheet with the d	correspondence add	ress
THE REPLY FILED <u>09 May 2005</u> FAILS TO PLACE THIS APP			
 The reply was filed after a final rejection, but prior to or of this application, applicant must timely file one of the follow places the application in condition for allowance; (2) a Not (3) a Request for Continued Examination (RCE) in complete following time periods: The period for reply expires 3 months from the mailing date of 	owing replies: (1) an amendment, a ptice of Appeal (with appeal fee) in liance with 37 CFR 1.114. The replied the final rejection.	ffidavit, or other evide compliance with 37 (ly must be filed within	ence, which OFR 41.31; or n one of the
b) The period for reply expires on: (1) the mailing date of this Adviewent, however, will the statutory period for reply expire later that Examiner Note: If box 1 is checked, check either box (a) or (b).	an SIX MONTHS from the mailing date o	f the final rejection.	
MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f)).		
Extensions of time may be obtained under 37 CFR 1.136(a). The date on been filed is the date for purposes of determining the period of extension a CFR 1.17(a) is calculated from: (1) the expiration date of the shortened sta above, if checked. Any reply received by the Office later than three months earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL 2. The Notice of Appeal was filed on A brief in comp	nd the corresponding amount of the fee. atutory period for reply originally set in the safter the mailing date of the final rejection	The appropriate extension final Office action; or (2) on, even if timely filed, ma	on fee under 37 as set forth in (b) ay reduce any
of filing the Notice of Appeal (37 CFR 41.37(a)), or any existince a Notice of Appeal has been filed, any reply must be AMENDMENTS	xtension thereof (37 CFR 41.37(e))), to avoid dismissal o	of the appeal.
3. The proposed amendment(s) filed after a final rejection, (a) They raise new issues that would require further co (b) They raise the issue of new matter (see NOTE belo (c) They are not deemed to place the application in bet appeal; and/or	nsideration and/or search (see NO w);	TE below);	
(d) They present additional claims without canceling a NOTE: (See 37 CFR 1.116 and 41.33(a)).	corresponding number of finally re	jected claims.	
 4. The amendments are not in compliance with 37 CFR 1.1 5. Applicant's reply has overcome the following rejection(s) 6. Newly proposed or amended claim(s) would be all 	: <u>102(b) and 112/2nd paragraph</u> .		
the non-allowable claim(s).	nowable it submitted in a separate,	, umery nied amendm	ent canceling
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is provided that the status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to:	☑ will not be entered, or b) ☐ w vided below or appended.	ill be entered and an	explanation of
Claim(s) rejected: <u>1-13,17,20,26-30,35 and 36</u> . Claim(s) withdrawn from consideration:			
AFFIDAVIT OR OTHER EVIDENCE			
8. The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and and was not earlier presented. See 37 CFR 1.116(e).	ut before or on the date of filing a N d sufficient reasons why the affida	lotice of Appeal will <u>n</u> vit or other evidence i	ot be entered s necessary
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary	vercome <u>all</u> rejections under appea y and was not earlier presented. S	al and/or appellant fai see 37 CFR 41.33(d)(ils to provide a 1).
10. ☐ The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER		-	
11. The request for reconsideration has been considered but	,		
12. Note the attached Information Disclosure Statement(s).			
	30	PERVISORY PATENT	EXAMINER

Art Unit: 1624

ADVISORY ACTION

Applicant's amendment of 5-09-05 has been fully considered. Although the amended claims and argument have overcome the previous rejections of 112/2nd and 102(b) based on **Kawakita et. al.** (US'039), but they have not placed this application in condition for allowance in view of the following reasons:

- Applicant's argument has not overcome the previous 103 rejection based on the combined teachings of Gotto et. al. (US'800), Tobin et. al. and Lai et. al.
- Applicant's Documents 1 and 2 are appreciated; however, they do not address the effect of Gotto's compounds (compounds # 38 and 40 in Table 63) on the urinary bladder. Note, Gotto's compounds are **not** distigmine, neostigmine, pyridostigmine, bethanechol, and atropine. Therefore, the results in those two documents are not unexpected or superior over the activity of Gotto's compounds.
- It is rather irrational for Gotto's compounds (which are **the same as** the two recited in the instant claim 13) to inhibit AchE, yet they do not have an effect on the bladder as recited in the instant method claims. The teachings of Tobin et. al. and Lai et. al. even supplement Gotto's teaching by providing the relationship of cholinergic receptors on the bladder a point which applicant's argument has failed to address.
- As amended, claim 11 lacks antecedent basis because it recites many rings for "Ar" that is not recited in claim 1.

Art Unit: 1624

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tamthom N. Truong whose telephone number is 571-272-0676. The examiner can normally be reached on M-F (10:00-6:30).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached on 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Tamthom N. Truong

Examiner

Art Unit 1624

5-16-05

JAMES O. WILSON

SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600